NCT05899140View on ClinicalTrials.gov

Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

March 29, 2026

Study Completion Date

July 31, 2026

Conditions
Skin InfectionStaphylococcal InfectionsStaphylococcus Aureus Infection
Interventions
DRUG

Clindamycin

Clindamycin will be administered at a dose of 450 mg TDS (oral) or 10 mg/kg/dose QID iv (maximum 600mg QID iv) for a maximum of 7 days

OTHER

Standard of care

Standard of care

Trial Locations (1)

Unknown

RECRUITING

Masanga Hospital, Masokori

All Listed Sponsors
lead

Frieder Schaumburg

OTHER